https://scholars.lib.ntu.edu.tw/handle/123456789/531664
標題: | Pentoxifylline: A potential therapy for chronic kidney disease | 作者: | SHUEI-LIONG LIN YUNG-MING CHEN WEN-CHIH CHIANG TUN-JUN TSAI Chen Wan Yu |
公開日期: | 2004 | 卷: | 9 | 期: | 4 | 起(迄)頁: | 198-204 | 來源出版物: | Nephrology | 摘要: | Almost all forms of chronic kidney disease progressing to end-stage kidney failure are characterized by diffuse fibrosis, a final common pathway converging from multiple pathogenetic networks regardless of the initial injury. Four principal interventions including glycaemic and blood pressure control, dietary protein restriction, and angiotensin II blockade have been proven to slow progression of diabetic and/or non-diabetic chronic kidney disease. However, the ultimate solution to halt disease progression in the long term is still pending. Because of the pathogenetic complexity of kidney disease, multidrug intervention with the least side-effects should, without doubt, be the next step to stop kidney disease progression. Animal and cellular studies have demonstrated the rationale for pentoxifylline (i.e. its effects against cell proliferation, inflammation, and extracellular matrix accumulation) in the treatment of chronic kidney disease induced by immune- or non-immune-mediated mechanisms. Limited human studies have proven its efficacy in reducing proteinuria in patients with diabetes receiving angiotensin-converting enzyme inhibitors, and in patients with nephrotic syndrome refractory to conventional immunosuppressive therapy. Moreover, monotherapy with pentoxifylline markedly reduces proteinuria in patients with membranous nephropathy. Further studies are required to examine whether pentoxifylline can improve the renal outcome in patients receiving interventions with proven efficacy. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-4844220823&doi=10.1111%2fj.1440-1797.2004.00267.x&partnerID=40&md5=09e76120669922e6ba36c8a37ae58f41 https://scholars.lib.ntu.edu.tw/handle/123456789/531664 |
ISSN: | 1320-5358 | DOI: | 10.1111/j.1440-1797.2004.00267.x | SDG/關鍵字: | angiotensin receptor antagonist; collagen type 1; collagen type 3; connective tissue growth factor; cyclic AMP dependent protein kinase; dipeptidyl carboxypeptidase inhibitor; fibroblast growth factor 2; gamma interferon; interleukin 1beta; interleukin 6; interleukin 8; monocyte chemotactic protein 1; pentoxifylline; phosphodiesterase inhibitor; platelet derived growth factor; RANTES; reactive oxygen metabolite; reduced nicotinamide adenine dinucleotide phosphate; transforming growth factor beta1; tumor necrosis factor alpha; antiinflammatory activity; blood pressure regulation; cell proliferation; chronic kidney disease; clinical trial; diabetic nephropathy; disease course; dizziness; drug efficacy; drug mechanism; dyspepsia; glucose blood level; human; kidney failure; kidney fibrosis; membranous glomerulonephritis; nausea; nephrotic syndrome; non insulin dependent diabetes mellitus; nonhuman; priority journal; protein restriction; proteinuria; review; Animals; Anti-Inflammatory Agents; Cell Division; Disease Progression; Extracellular Matrix; Glomerular Mesangium; Humans; Kidney; Kidney Failure, Chronic; Pentoxifylline; Phosphodiesterase Inhibitors; Protective Agents |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。